Tanvex BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 08, 2023
Share
Tanvex BioPharma, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 17.08 million compared to TWD 3.04 million a year ago. Net loss was TWD 505.54 million compared to TWD 427.06 million a year ago. Basic loss per share from continuing operations was TWD 3.89 compared to TWD 3.63 a year ago. Diluted loss per share from continuing operations was TWD 3.89 compared to TWD 3.63 a year ago.
For the six months, sales was TWD 47.22 million compared to TWD 6.17 million a year ago. Net loss was TWD 1,113.74 million compared to TWD 758.9 million a year ago. Basic loss per share from continuing operations was TWD 8.99 compared to TWD 6.45 a year ago. Diluted loss per share from continuing operations was TWD 8.99 compared to TWD 6.45 a year ago.
Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.
TANVEX BIOPHARMA, INC. 
